Moreover, Ru compounds can effectively bind to the serum transferrin receptor, which is highly expressed in tumor cells, thus increasing the number of Ru–transferrin complexes that could preferably be delivered at the tumor site [14,15]. Here, TFRC is linked to neoplasm.